Numerous studies on human AD biomarkers have demonstrated that the cerebral Aβ deposition begins many years before other AD-associated changes [i.e., increased tau in the cerebrospinal fluid (CSF), decreased cerebral glucose metabolism, brain atrophy, and clinical dementia]. The gene discussed is MAPT; the disease is Alzheimer disease.